Pharmaceutical giant Merck & Co. is currently undergoing a criminal investigation by the US Department of Justice for its marketing and selling activities for three prescription drugs.
The drugs being reviewed in the federal subpoena are Temodar, a brain cancer treatment, and PegIntron and Intron A, cancer and hepatitis C medications. Merck acquired the three drugs during its $41 billion merger with Schering-Plough in 2009.
According to a statement made by Ronald Rogers, a spokesman for the pharmaceutical company, Merck is cooperating with the investigations.
In March, Adele Ambrose, CCO at Merck for more than three years, told PRWeek that the company was focusing on improving its reputation, especially after the big merger, which nearly doubled the size of its global communications team.
Ambrose said the company not only wants to establish what drives reputation with healthcare providers and consumers, it also wants to align more of its products with prevention and wellness and enhance CSR efforts, as well.
Merck is also still involved in a lawsuit regarding the company's alleged misrepresentation of safety facts about the painkiller Vioxx, which was pulled from the market in 2004.